MXPA02011162A - Proteina cln2 recombinante de humano y metodos para su reduccion y uso. - Google Patents

Proteina cln2 recombinante de humano y metodos para su reduccion y uso.

Info

Publication number
MXPA02011162A
MXPA02011162A MXPA02011162A MXPA02011162A MXPA02011162A MX PA02011162 A MXPA02011162 A MX PA02011162A MX PA02011162 A MXPA02011162 A MX PA02011162A MX PA02011162 A MXPA02011162 A MX PA02011162A MX PA02011162 A MXPA02011162 A MX PA02011162A
Authority
MX
Mexico
Prior art keywords
cln2 protein
production
methods
recombinant human
human cln2
Prior art date
Application number
MXPA02011162A
Other languages
English (en)
Inventor
Peter Lobel
Original Assignee
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med filed Critical Univ New Jersey Med
Publication of MXPA02011162A publication Critical patent/MXPA02011162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
MXPA02011162A 2000-05-11 2001-05-11 Proteina cln2 recombinante de humano y metodos para su reduccion y uso. MXPA02011162A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20340700P 2000-05-11 2000-05-11
US09/852,918 US20020006400A1 (en) 2000-05-11 2001-05-10 Recombinant human CLN2 protein and methods of its production and use
PCT/US2001/015386 WO2001085200A2 (en) 2000-05-11 2001-05-11 Recombinant human cln2 protein and methods of its production and use

Publications (1)

Publication Number Publication Date
MXPA02011162A true MXPA02011162A (es) 2003-07-28

Family

ID=26898578

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011162A MXPA02011162A (es) 2000-05-11 2001-05-11 Proteina cln2 recombinante de humano y metodos para su reduccion y uso.

Country Status (10)

Country Link
US (5) US20020006400A1 (es)
EP (1) EP1292326B1 (es)
JP (1) JP4843774B2 (es)
AT (1) ATE360438T1 (es)
AU (1) AU2001263085A1 (es)
BR (1) BR0110746A (es)
CA (1) CA2408380C (es)
DE (1) DE60128084T2 (es)
MX (1) MXPA02011162A (es)
WO (1) WO2001085200A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
ES2432653B1 (es) * 2012-05-23 2015-09-17 Centro De Investigacion Biomedica En Red De Enfermedades Raras Un procedimiento y kit para el diagnostico diferencial de una enfermedad que cursa con afectación muscular.
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
JP2022546042A (ja) 2019-08-29 2022-11-02 バイオマリン ファーマシューティカル インコーポレイテッド 小児対象のｃｌｎ２疾患を治療するための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) * 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use

Also Published As

Publication number Publication date
US20020006400A1 (en) 2002-01-17
US20110014172A1 (en) 2011-01-20
WO2001085200A2 (en) 2001-11-15
JP2004519415A (ja) 2004-07-02
EP1292326B1 (en) 2007-04-25
US20130273018A1 (en) 2013-10-17
US8277800B2 (en) 2012-10-02
DE60128084T2 (de) 2008-01-03
US7811559B2 (en) 2010-10-12
CA2408380C (en) 2012-04-17
ATE360438T1 (de) 2007-05-15
US8029781B2 (en) 2011-10-04
CA2408380A1 (en) 2001-11-15
JP4843774B2 (ja) 2011-12-21
DE60128084D1 (de) 2007-06-06
US20120014935A1 (en) 2012-01-19
AU2001263085A1 (en) 2001-11-20
EP1292326A2 (en) 2003-03-19
WO2001085200A3 (en) 2002-04-11
BR0110746A (pt) 2003-07-22
US20090022701A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
MXPA05013564A (es) Proteinas de fusion.
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
HK1104836A1 (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
BR0209541A (pt) Uso das imidazotriazinonas 2-fenil-substituìdas
WO2005046614A3 (en) System for treating and preventing breast cancer
MXPA02011162A (es) Proteina cln2 recombinante de humano y metodos para su reduccion y uso.
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
HUP0401913A2 (hu) Bromhidrosis kezelésére és megelőzésére szolgáló gyógyszerkészítmény
HK1047549A1 (en) Il6ril6 chimera for the treatment of neurodegeneraive diseases.
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP0967276A3 (en) Anti-tumor agent comprising salmosin
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
RS20060023A (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
EP1143996A4 (en) Method of treating chronic cardiac disease
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
NZ514691A (en) Method to type prion proteins
WO2002008422A1 (fr) Nouveau polypeptide, proteine du myotube humaine 10.56, et polynucleotide codant ce polypeptide
UA32384A (uk) Спосіб лікування пародонтиту

Legal Events

Date Code Title Description
FG Grant or registration